切换至 "中华医学电子期刊资源库"
高级检索
中华肺部疾病杂志(电子版)

中华肺部疾病杂志(电子版) ›› 2024, Vol. 17 ›› Issue (04) : 558 -562. doi: 10.3877/cma.j.issn.1674-6902.2024.04.010

论著

血清PTX3表达与非小细胞肺癌骨转移的相关性分析
李多1, 郝昭昭1, 陈延伟1, 南岩东1,†()   
  1. 1. 710038　西安，空军军医大学唐都医院呼吸与危重症医学科
  • 收稿日期:2024-01-23 出版日期:2024-08-25
  • 通信作者: 南岩东
  • 基金资助:
    唐都医院高层次人才启动项目(2021YFJH0011)

Correlation analysis of serum PTX3 expression and bone metastasis in non-small cell lung cancer

Duo Li1, Zhaozhao Hao1, Yanwei Chen1, Yandong Nan1,†()   

  1. 1. Department of Respiratory and Critical Care Medicine, Tangdu Hospital, Air Force Military Medical University, Xi′an, 710038, China
  • Received:2024-01-23 Published:2024-08-25
  • Corresponding author: Yandong Nan
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

李多, 郝昭昭, 陈延伟, 南岩东. 血清PTX3表达与非小细胞肺癌骨转移的相关性分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 558-562.

Duo Li, Zhaozhao Hao, Yanwei Chen, Yandong Nan. Correlation analysis of serum PTX3 expression and bone metastasis in non-small cell lung cancer[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 558-562.

目的

分析血清正五聚蛋白3(pentraxin 3, PTX3)表达与非小细胞肺癌(non-small cell lung cancer, NSCLC)骨转移的相关性及临床意义。

方法

选取2022年9月至2023年7月我院收治的184例转移性NSCLC患者，NSCLC骨转移69例为观察组，NSCLC非骨转移115例为对照组。收集患者临床资料，采用酶联免疫吸附法(enzyme-linked immunosorbent assay, ELISA)检测血清PTX3表达水平。对比两组血清PTX3含量，分析血清PTX3表达与NSCLC骨转移的相关性，比较治疗前后NSCLC骨转移血清PTX3表达。采用受试者工作特征曲线(receiver operating characteristic, ROC)判断血清PTX3对NSCLC骨转移诊断。

结果

两组性别、年龄差异无统计学意义(P>0.05)。观察组骨转移69例，对照组淋巴结转移40例、肺转移31例、脑转移21例、肝转移14例、肾上腺转移12例。观察组血清PTX3 104.80(175.48)ng/ml高于对照组21.48(22.02)ng/ml(P<0.05)。血清PTX3表达与NSCLC骨转移者性别、年龄、癌症史、吸烟指数、BMI指数、病理类型、原发灶位置、单器官转移、转移灶数量、骨转移性质、血钙、血碱性磷酸酶差异无统计学意义(P>0.05)。治疗前后NSCLC骨转移血清PTX3表达差异无统计学意义(P>0.05)。血清PTX3诊断NSCLC骨转移的ROC曲线下面积为0.860(95%CI：0.802～0.919)，最佳诊断截断值为35.385 ng/ml，灵敏度和特异度分别为0.855和0.748。

结论

血清PTX3高表达与NSCLC骨转移密切相关，对NSCLC骨转移诊断具有临床意义。

关键词: 非小细胞肺癌, 正五聚蛋白3, 骨转移, 相关性分析
Objective

To analyze the correlation and clinical significance of serum pentraxin 3 (PTX3) expression with bone metastasis of non-small cell lung cancer (NSCLC).

Methods

A total of 184 metastatic NSCLC patients treated in Tangdu Hospital from September 2022 to July 2023 were selected. 69 cases of NSCLC bone metastasis were the observation group, and 115 cases of NSCLC non-bone metastasis were the control group. The clinical information of patients was collected, and the expression level of serum PTX3 was detected by enzyme-linked immunosorbent assay (ELISA). Compared serum PTX3 content of two groups, we analyze the correlation of PTX3 expression with NSCLC bone metastases and compared serum PTX3 expression in NSCLC bone metastases before and after treatment. Receiver operating characteristic (ROC) curve was used to determine the diagnostic value of serum PTX3 for NSCLC bone metastasis.

Results

There were no significant differences in gender and age between the two groups (P>0.05). There were 69 cases of bone metastasis in the observation group and 40 cases of lymph node metastasis, 31 cases of lung metastasis, 21 cases of brain metastasis, 14 cases of liver metastasis and 12 cases of adrenal metastasis in the control group. The serum PTX3 in the observation group was 104.80 (175.48) ng/ml, which was higher than that in the control group 21.48 (22.02) ng/ml (P<0.05). There were no significant differences of serum PTX3 expression in NSCLC bone metastasis patients with different clinical characteristics, including gender, age, history of cancer, smoking index, BMI index, pathological type, primary tumor location, single organ metastasis, number of metastatic lesions, nature of bone metastasis, blood calcium and serum alkaline phosphatase (P>0.05). There was no significant difference in the expression of serum PTX3 in NSCLC patients with bone metastasis before and after clinical treatment(P>0.05). The area under ROC curve of serum PTX3 in the diagnosis of NSCLC with bone metastasis was 0.860(95%CI: 0.802~0.919), with the optimal diagnostic cut-off value, sensitivity and specificity of 35.385 ng/ml, 0.855 and 0.748, respectively.

Conclusions

The high expression of serum PTX3 is closely related to the bone metastasis of NSCLC, which has a good diagnostic value for NSCLC bone metastasis and clinical significance.s

Key words: Non-small cell lung cancer, Pentraxin 3, Bone metastasis, Correlation analysis
表1 两组转移性NSCLC患者血清PTX3表达水平比较
组　别 转移器官 例数 M(IQR)(ng/ml) H值 P值
观察组 骨转移 69 104.80(175.48) 71.44 0.000
对照组 肺转移ab 31 24.06(15.57)    
  脑转移b 21 20.61(29.92)    
  肝转移b 14 22.53(23.72)    
  肾上腺转移b 12 23.75(20.78)    
  淋巴结转移bc 40 21.91(41.84)    
表2 NSCLC骨转移临床特征与血清PTX3表达关系
临床资料 变　量 例数 PTX3(ng/ml) P值
性别       0.288
  男 38 86.27(176.91)  
  女 31 116.63(176.07)  
年龄(岁)       0.387
  ≤60 34 102.55(151.93)  
  >60 35 116.63(245.80)  
癌症家族史       0.226
  无 59 89.52(162.47)  
  有 10 166.07(290.60)  
吸烟指数(支年)       0.475
  0 41 89.52(167.56)  
  0～400 6 197.95(94.32)  
  ≥400 22 93.94(254.22)  
BMI指数(kg/m2)       0.239
  <18.50 8 113.51(228.44)  
  18.50～23.99 41 81.78(132.45)  
  24.00～27.99 15 126.17(167.58)  
  ≥28.00 5 216.54(151.66)  
病理类型       0.183
  腺癌 61 98.04(196.39)  
  鳞癌 8 37.90(243.91)  
原发灶位置       0.408
  中央 23 87.43(136.81)  
  周围 43 104.86(195.81)  
单器官转移       0.870
  否 51 100.30(176.56)  
  是 18 115.52(206.10)  
骨转移灶数量(个)       0.912
  ≤2 21 104.80(133.67)  
  3～5 26 91.26(158.54)  
  >5 22 133.33(215.81)  
骨转移性质       0.983
  溶骨性 47 104.86(183.48)  
  成骨性 9 104.80(209.60)  
  混合性 13 89.52(182.61)  
高钙血症       0.264
  否 65 100.30(161.27)  
  是 4 291.22(207.88)  
高碱性磷酸酶血症       0.055
  否 41 87.43(119.90)  
  是 28 189.10(243.64)  
图1 血清PTX3诊断NSCLC骨转移的ROC曲线M(IQR)
1
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024，74(3): 229-263.
2
吴国明，钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
3
Shi S, Wang H, Liu X, et al. Prediction of overall survival of non-small cell lung cancer with bone metastasis: an analysis of the Surveillance, Epidemiology and End Results (SEER) database[J]. Transl Cancer Res, 2021, 10(12): 5191-5203.
4
Cho YJ, Cho YM, Kim SH, et al. Clinical analysis of patients with skeletal metastasis of lung cancer[J]. BMC Cancer, 2019, 19(1): 303.
5
Li Y, Zhang S, Liu J, et al. The pentraxin family in autoimmune disease[J]. Clin Chim Acta, 2023, 551: 117592.
6
Giacomini A, Ghedini GC, Presta M, et al. Long pentraxin 3: A novel multifaceted player in cancer[J]. Biochim Biophys Acta Rev Cancer, 2018, 1869(1): 53-63.
7
Li D, Hao Z, Nan Y, et al. Role of long pentraxin PTX3 in cancer[J]. Clin Exp Med, 2023, 23(8): 4401-4411.
8
Bottazzi B, Inforzato A, Messa m, et al. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling[J]. J Hepatol, 2016, 64(6): 1416-1427.
9
Choi B, Lee EJ, Song DH, et al. Elevated pentraxin 3 in bone metastatic breast cancer is correlated with osteolytic function[J]. Oncotarget, 2014, 5(2): 481-492.
10
Choi B, Lee EJ, Shin MK, et al. Upregulation of brain-derived neurotrophic factor in advanced gastric cancer contributes to bone metastatic osteolysis by inducing long pentraxin 3[J]. Oncotarget, 2016, 7(34): 55506-55517.
11
Granata V, Strina D, Schiavone ML, et al. Genetic deficiency of the long pentraxin 3 affects osteogenesis and osteoclastogenesis in homeostatic and inflammatory conditions[J]. Int J Mol Sci, 2023, 24(23): 16648.
12
Coleman R, Hadji P, Body JJ, et al. Bone health in cancer: ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2020, 31(12): 1650-1663.
13
崔永元，宋　敏，刘乾坤，等. 甲状旁腺素对骨代谢相关疾病的影响研究进展[J]. 系统医学，2023, 8(15): 195-198.
14
周于琳，冯正平. 糖皮质激素诱导骨质疏松发病机制的研究进展[J]. 中国骨质疏松杂志，2023, 29(2): 288-291.
15
黄毅勇. 慢性肾病矿物质和骨代谢异常的血清学诊断的临床研究[J/CD]. 临床检验杂志(电子版), 2020, 9(1): 70.
16
Thomson M, Scott A, Trost S, et al. Low screening rates and high prevalence of osteoporosis in cirrhosis: A real-world retrospective analysis[J]. Aliment Pharmacol Ther, 2024, 59(4): 535-546.
17
Jansen RB, Nilsson J, Buch-Larsen K, et al. Treatment effect of zoledronic acid in chronic non-bacterial osteomyelitis of the jaw: A case series[J]. Calcif Tissue Int, 2024, 114(2): 129-136.
18
Da SILVA G T, Bergmann A, Thuler LCS. Incidence and risk factors for bone metastasis in non-small cell lung cancer[J]. Asian Pac J Cancer Prev, 2019, 20(1): 45-51.
19
Sterling JA, Edwards JR, Martin TJ, et al. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior[J]. Bone, 2011, 48(1): 6-15.
20
Wu S, Pan Y, Mao Y, et al. Current progress and mechanisms of bone metastasis in lung cancer: a narrative review[J]. Transl Lung Cancer Res, 2021, 10(1): 439-451.
21
De Leon-Oliva D, Barrena-Blázquez S, Jiménez-Álvarez L, et al. The RANK-RANKL-OPG system: A multifaceted regulator of homeostasis, immunity, and cancer[J]. Medicina (Kaunas), 2023, 59(10): 1752.
22
Chu T, Teng J, Jiang L, et al. Lung cancer-derived Dickkopf1 is associated with bone metastasis and the mechanism involves the inhibition of osteoblast differentiation[J]. Biochem Biophys Res Commun, 2014, 443(3): 962-968.
23
Jiang T, Zeng Q, He J. Do alkaline phosphatases have great potential in the diagnosis, prognosis, and treatment of tumors？[J]. Transl Cancer Res, 2023，12(10): 2932-2945.
24
Xie T, Chen S, Hao J, et al. Roles of calcium signaling in cancer metastasis to bone[J]. Explor Target Antitumor Ther, 2022，3(4): 445-462.
25
郭飞虎，成伟华，费月英，等. Na～(18)F PET/CT用于恶性肿瘤骨转移诊断的Meta分析[J]. 标记免疫分析与临床，2019, 26(5): 786-794.
26
陈　凤，崔亚利. 骨转移瘤影像学检查研究概述[J]. 医学综述，2019, 25(1): 134-138.
27
Chai X, Yinwang E, Wang Z, et al. Predictive and prognostic biomarkers for lung cancer bone metastasis and their therapeutic value[J]. Front Oncol, 2021, 11: 692788.
28
孟　超，汤传昊，梁　军. 肺癌骨转移诊断标记物研究进展[J]. 中国肺癌杂志，2018, 21(8): 615-619.
29
李秋实，杨　洁，庄　琰，等. 观察血清肿瘤标志物在肺癌骨转移诊断中的价值[J]. 航空航天医学杂志，2021, 32(12): 1432-1433.
30
Zang S, He Q, Bao Q, et al. Establishment and validation of a novel survival prediction scoring algorithm for patients with non-small-cell lung cancer spinal metastasis[J]. Int J Clin Oncol, 2019, 24(9): 1049-1060.
[1] 胡思平, 熊性宇, 徐航, 杨璐. 衰老相关分泌表型因子在前列腺癌发生发展中的作用机制[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 425-434.
[2] 李鑫钊, 张廷涛, 朱峰, 刘金山, 刘大闯. 血纤维蛋白原、D-二聚体及碱性磷酸酶诊断前列腺癌骨转移的价值分析[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 459-463.
[3] 赵蒙蒙, 黄洁, 余荣环, 王葆青. 过表达小GTP酶Rab32抑制非小细胞肺癌细胞侵袭性生长[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 512-518.
[4] 张桂萍, 丘勇林, 湛绮婷, 孙乐栋. 晚期非小细胞肺癌血清Ape1/Ref-1对放射性肺损伤发生的预测意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 519-523.
[5] 韩晓宇, 李柯育, 赵志菲, 高建平. SNHG17过表达对非小细胞肺癌切除术预后的意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 543-547.
[6] 刘松, 张进召, 贾艳云. 帕博利珠单抗治疗晚期非小细胞肺癌反应降低与抗生素预处理的关系[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 553-557.
[7] 陈旭, 牛凯, 孙建国. 放疗联合免疫治疗对驱动基因阴性NSCLC的困惑分析及应对策略[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 341-348.
[8] 杨静, 附舰, 康艳霞. 血浆ctDNA T790M突变和总代谢肿瘤体积对晚期EGFR突变NSCLC患者TKIs治疗及预后意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 379-384.
[9] 赵海燕, 靳海涛, 孔莺, 何瑞远. 血浆NGS-ctDNA对EGFR-TKIs治疗晚期NSCLC患者的预后意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 385-391.
[10] 白丽丽, 江榆, 黄亮亮, 白莹, 张敏. 作业疗法在非小细胞肺癌患者术后康复中应用分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 411-415.
[11] 李静静, 许金花, 吴国峰, 任亚俊, 张骞云. 伏美替尼一线治疗EGFR突变晚期NSCLC脑转移的临床分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 426-429.
[12] 尹炳驿, 张楚楚, 刘艺, 林洪生. 益气清金汤加味治疗晚期非小细胞肺癌的临床分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 462-465.
[13] 罗孝平, 封敏, 黄川, 唐茜, 蒋艳, 胡莉丽. 渐进式抗阻训练干预在非小细胞肺癌中的临床应用[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 472-474.
[14] 张迅夫, 马金山, 蒋云龙, 加纳提·托勒恒, 侯昌剑, 萨伍提·斯拉吉丁. GATA3在非小细胞肺癌组织中的表达及临床病理意义[J]. 中华胸部外科电子杂志, 2024, 11(03): 175-179.
[15] 李子健, 王锐, 钟云鹏, 张迪轩, 梁韵娟, 杨超, 何建行, 李树本. 自体肺移植术在胸部恶性肿瘤中的临床应用[J]. 中华胸部外科电子杂志, 2024, 11(03): 193-200.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号